30 results about "Insulinoma" patented technology

The invention provides peptide used for preventing and treating diabetes. According to the weak immunogen of antigen polypeptide, a fragment of antigenic epitope (IPALDSLTPANED) derived from HSP60 is inserted into the downstream of a linear B-epitope sequence HGDTTDEYQD in a membrane closing area of insulinoma associated protein 2 to form the peptide. According to the peptide, the generation times of NOD (nonobese diabetic) mice diabetes can be reduced obviously, so that the novel peptide plays the role of preventing and treating I-type diabetes. Meanwhile, the peptide can be used for transgenic animals and recombinant microorganisms, so that the transgenic animals and the recombinant microorganisms can be used for producing the peptide or preparing oral vaccine for preventing and treating diabetes and related diseases of diabetes.

The present invention is directed to the identification of a biomarker specifically located in the plasma membrane of pancreatic beta cells. It was selected by a Systems Biology approach on Massively Parallel Signal Sequencing datasets obtained in human islets and Affymetrix microarray datasets on human islets, purified rat primary beta and non beta cells and insulinoma cells. Based on a set of specific features the biomarker is a unique candidate for imaging and targeting strategies to study the pancreatic beta cell mass in health and disease (T1 D, T2D, pancreatic cancers, obesity, islet transplantation, beta cell regeneration). The five specific features of the selected biomarkers are: 1) Preferentially expressed in pancreatic islets as compared to surrounding tissues; 2) Higher expression in pancreatic beta cells than in pancreatic alpha cells or than in other islet non-beta cells; 3) Expression levels in pancreatic beta cells are higher or comparable to glucokinase which is an enzyme specifically expressed in the pancreatic beta cell; 4) Located in the membrane and as such targetable with antibodies, peptides or small molecules which allows imaging, targeting and immunohistochemistry; and 5) Expression is not induced during the process of inflammation of the beta cell mass and the protein is not enriched in T-cells and dendritic cells or in other cells participating in the inflammation process.

The present invention provides an impaired glucose tolerance ameliorating drug and a therapeutic drug for lifestyle-related diseases, particular an antidiabetic drug, which contain a CXCR3 agonist as an active ingredient; a hypoglycemia ameliorating drug, a therapeutic drug for insulinoma or an anti-obesity drug containing a CXCR3 antagonist as an active ingredient; a method of screening for a new CXCR3 ligand using CXCR3 and a known CXCR3 ligand; a method of screening a CXCR3 ligand, which uses a co-expression system of CXCR3 and a coupling G protein; and a diagnostic method for type II diabetes, which includes detecting an amount of a CXCR3 ligand expressed in a biological sample.

The invention discloses B cell epitope for xanthine oxidase and an antigen peptide containing the epitope. The antigen peptide is prepared by the following steps: B cell epitope for xanthine oxidase is connected to a linear B cell epitope FEYQD which is at a membrane-proximal region of insulinoma-associated protein-2 by a flexible peptide in a series connection, and a terminal is connected to a N terminal of Th2 auxiliary epitope P2 of P277 by a flexible peptide in a series connection. Serum which is obtained by immunization of mice with the antigen peptide is detected by Western blot, results show that an antibody which is specifically combined with xanthine oxidase is generated, and the antigen peptide is used for detecting xanthine oxidase; serum of the mice which are immunized by the antigen peptide can be used for inhibiting exogenous activity of xanthine oxidase, the difference between the inhibition rate of xanthine oxidase and the inhibition rate of allopurinol is not substantial (P>0.5), and the serum can be used for preparing xanthine oxidase inhibitor; the antigen peptide is used for treating gout, hepatopathy, nephrosis, atherosclerotic, diabetes, senile dementia, eye diseases, cardiovascular diseases, and other diseases due to xanthine oxidase abnormity, uric acid abnormity and oxidative stress disorder with important theoretical values and wide application prospects.

The invention is directed to the use of at least one CBx modulator wherein the CBx modulator is selected from the group consisting of CB1 agonists; CB2 agonists; CB2 partial agonists; CB2 antagonists; CB2 inverse agonists; and dually acting compounds which are both a CB1 agonist and a CB2 agonist; and mixtures thereof, as KATP channel modulator for the prophylaxis, treatment, delayed progression, delayed onset and/or inhibition of a variety of disease conditions including obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence in mammals and humans. The invention further relates to methods of treating, preventing, delaying progression of, delaying onset of and/or inhibiting a variety of disease conditions including obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence in mammals and humans comprising administering to a subject in need thereof an effective amount of at least one CBx modulator having KATP channel modulating properties.

The invention discloses <68>Ga marked NOTA-MAL-Cys<39>-exendin-4 compound as well as a preparation method and application thereof. The <68>Ga-NOTA-MAL-Cys<39>-exendin-4 is prepared from <68>Ga marked precursor compound of NOTA-MAL-Cys<39>-exendin-4. Synthesizing time of the <68>Ga-NOTA-MAL-Cys<39>-exendin-4 disclosed by the invention is about 25min, a labeling yield is as high as 80% or more, HPLC determination shows that a product radiochemical purity is larger than 98%, and the marked product of the <68>Ga-NOTA-MAL-Cys<39>-exendin-4 can be specifically combined with glucagon-like peptide-1 receptor (GLP-1R), is a GLP-1 receptor photographic developer having potential and is suitable for being applied to clinical insulinoma diagnosis.

The invention is directed to pharmaceutical compositions comprising pharmacologically effective quantities of each of a) at least one KATP channel modulator as a first active agent and b) at least one CBx modulator as a second active agent. The invention further relates to the use of such compositions and to methods of treating, preventing, delaying progression of, delaying onset of and/or inhibiting a variety of disease conditions including obesity, diabetes mellitus, metabolic syndrome, syndrome X, insulinoma, familial hyperinsulemic hypoglycemia, male pattern baldness, detrusor hyperreactivity, asthma, neuroprotection, epilepsy, analgesia, cardioprotection, angina, cardioplegia, arrhythmia, coronary spasm, peripheral vascular disease, cerebral vasospasm, appetite regulation, neurodegeneration, pain - including neuropathic pain and chronic pain - and impotence in mammals and humans by administering such compositions to subjects in need thereof. The invention also is directed to processes of manufacturing such compositions.

The present invention relates to a screening method for determining whether a substance of interest is a substance which alters GPR40-mediated cell stimulating activities, comprising using a substance of interest, a biomembrane containing GPR40, or cells containing said biomembrane, and phospholipase or salts thereof. According to the present invention, substances involved in insulin secretion can be screened. In addition, according to the present invention, substance useful for the prevention or treatment of diabetes, diabetic complications and degenerative diseases, hyperglycemia, polyuria, ketonemia, acidosis, insulin resistance, impaired glucose tolerance, neurodegenerative diseases, insulinoma, cancers, hyperinsulinemia, hyperglyceridemia, fatty liver, hypoglycemia due to insulin hypersecretion, arteriosclerosis, hyperlipidemia, cerebral stroke, obesity, various diseases induced by diabetes or obesity, and the like.

The invention belongs to the technical field of biology, particularly discloses an application of annexin V to the preparation of a medicine for delaying diabetes progression, and specifically comprises an application of the annexin V to the preparation of a medicine for the in preparing a medicament for improving physiological index and metabolism of diabetes, improving insulin signal pathway ofdiabetic model, improving pathological changes of diabetes liver, pancreas and kidney, improving diabetes serum creatinine and urea nitrogen levels, preventing diabetic renal complications or renal function damage and protecting insulinoma cells from apoptosis caused by diabetes inducer streptozotocin.

The invention provides monoclonal antibody 3H6 and related antibodies. The 3H6 antibody binds to an epitope within residues 28-36 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome, impaired insulin tolerance, impaired glucose tolerance, insulinomas, and related conditions.

The invention provides monoclonal antibody 6B8 and related antibodies. The 6B8 antibody binds to an epitope within residues 3-12 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome, impaired insulin tolerance, impaired glucose tolerance, insulinomas, and related conditions.

A chemical compound has the general formula: Ex4-linker-Sar(⁶⁴Cu)-Fl in which Ex4 is an extendin-4 analog; linker is a polyethylene glycol (PEG) chain, for example formed with four ethylene glycol residues; Fl is a photoluminescent moiety, and Sar(⁶⁴Cu) is an atom of copper-64 chelated in a sarcophagine moiety is useful as a multimodality imaging agent for detection and localization of insulinoma cells and β-cell masses.

The invention belongs to the field of radioactive drug markers, and concretely relates to a <18>-FBEM-Cys39-Exenatide marker, and a preparation method and an application thereof. The 39th serine (Ser39) at the N-terminal of Exenatide is replaced by cysteine (Cys39) to obtain a novel Exenatide analog, and the specific combination characteristic of the mercapto group of the analog and a marking prosthetic group (<18>-FBEM) is used to realize the positioning marking of Exenatide. Preclinical researches show that the marked product <18>-FBEM-Cys39-Exenatide can be specifically combined with a GLP-1 receptor, is a latent GLP-1 receptor developer, and is suitable for diagnosing insulinoma.

The invention belongs to the field of biomedicine, and provides application of insulinoma related protein 1 in preparation of a marker for diagnosis or prognosis evaluation of prostate neuroendocrinesmall cell carcinoma. The invention also provides a kit which comprises a reagent for detecting the insulinoma related protein 1. The marker INSM1 can be used for effectively distinguishing an adenocarcinoma accompanied by neuroendocrine differentiation subject from an adenocarcinoma accompanied by penem cell-like neuroendocrine differentiation subject so that accurate pathological detection of prostate cancer is realized; meanwhile, the marker has a good indication effect in the aspect of adenocarcinoma accompanied by neuroendocrine differentiation diagnosis, and has higher sensitivity and specificity compared with a clinically common diagnosis marker so that the occurrence of clinical misdiagnosis and missed diagnosis is reduced. In addition, the marker also has a good prediction effecton prognosis of prostate cancer, and is beneficial to recurrence monitoring and clinical early intervention of a subject.

The invention relates to application of a D1 receptor-based targeting molecular probe in pancreatic beta cell imaging, and belongs to the technical field of radiopharmaceutical chemistry. Experiments prove that the D1 receptor targeting molecular probe can be used for monitoring the number of pancreatic beta cells, so that a novel imaging probe can be provided for early diagnosis and curative effect monitoring of diabetes and insulinoma. In addition, a new thought can be provided for treatment of diabetes and insulinoma.

The invention provides recombinant G-17 protein, a gene for encoding the recombinant protein and application of the gene for encoding the recombinant protein. An amino acid sequence of the recombinantG-17 protein is shown in SEQ ID NO: 1 as shown in the description, and a base sequence of the gene for encoding the recombinant G-17 protein is shown in SEQ ID NO: 2 as shown in the description. According to the recombinant G-17 protein, the gene for encoding the recombinant protein and application of the gene for encoding the recombinant protein, after a G-17 antigen epitope sequence is connected with a sequence of a B cell epitope of insulinoma-related protein IA-2 and a Th2 cell epitope of a C terminal of P277 through flexible fragments, the amino acid sequence of the recombinant G-17 protein is formed; and mice are immunized against the recombinant G-17 protein, and an ELISA detection antibody titer value reaches 1:106, so that specific detection and recognition of G-17 are achieved,not only is the detection sensitivity enhanced, but also distortion of a detection result is avoided, the probability of subsequent screening of a high-specificity antibody is improved, and the time and the economic cost are saved.

The invention belongs to the field of biological medicine, and in particular relates to an application of beta-catenin and gene in a reagent for detecting insulinoma and an application of the beta-catenin and gene in drug screening of insulinoma drugs. Through the experiments of dissecting the remain of a transgenic mice, detecting the blood sugar and fasting insulin level, the influence relation of the beta-catenin to the generation of the insulinoma is researched. The experiment result shows that the beta-catenin and the insulinoma are in positive relation, once the lack of beta-catenin, the occurrence rate of the islet cell tumor is obviously reduced. The application provided by the invention has the beneficial effects that the mice with insulinoma can be fast and accurately diagnosed through the detection of beta-catenin, and the experimental data and theoretical basis are provided for the application of beta-catenin in the reagent for detecting the insulinoma and in the drug screening of the insulinoma drug in the clinical diagnosis.